Evidence map›Paper›PMID 26286833›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

Src and epidermal growth factor receptor mediate the pro-invasive activity of Bcl-w.

Eun Mi Kim, Jong Kuk Park, Sang-Gu Hwang, Hong-Duck Um

Abstract read
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Novel read-through fusion transcript Bcl2l2-Pabpn1 in glioblastoma cells.Journal of cellular and molecular medicine · 2022
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Eun Mi KimDivision of Radiation Cancer Biology, Korea Institute of Radiological and Medical Sciences, Nowon-ro 75, Nowon-gu, Seoul, 139-706, Korea.
Jong Kuk ParkDivision of Radiation Cancer Biology, Korea Institute of Radiological and Medical Sciences, Nowon-ro 75, Nowon-gu, Seoul, 139-706, Korea.
Sang-Gu HwangDivision of Radiation Cancer Biology, Korea Institute of Radiological and Medical Sciences, Nowon-ro 75, Nowon-gu, Seoul, 139-706, Korea.
Hong-Duck UmDivision of Radiation Cancer Biology, Korea Institute of Radiological and Medical Sciences, Nowon-ro 75, Nowon-gu, Seoul, 139-706, Korea. hdum@kirams.re.kr.
Korea Institute of Radiological and Medical Sciences · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Members of the Bcl-2 family are established regulators of cell death. However, recent studies have shown that they can also regulate cell migration, invasion, and cancer metastasis. These functions of cancer cells are promoted by pro-survival Bcl-2 proteins (Bcl-2, Bcl-XL, and Bcl-w) but are suppressed by pro-apoptotic members (Bax and Bak). We have previously shown that Bcl-w and Bcl-XL enhance the ability of respiratory complex-I to produce reactive oxygen species (ROS), stimulating the phosphoinositide 3-kinase (PI3K)-dependent invasion pathway. Here, we show that Bcl-w overexpression increases the phosphorylation of epidermal growth factor receptor (EGFR) and Src, and their interaction. Our results show that ROS production induced by Bcl-w activates Src, which then binds to and phosphorylates EGFR, leading to stimulation of the PI3K-dependent invasion pathway. Importantly, Bcl-w-induced cell invasion was prevented by treating cells with gefitinib (Iressa, ZD1839), an anticancer drug that directly inhibits EGFR. We also show that Bcl-XL can stimulate Src and EGFR phosphorylation, and that this function of Bcl-XL and Bcl-w is antagonized by Bax and Bak. Overall, this study demonstrates the involvement of Src and EGFR in the regulation of cellular invasiveness by Bcl-2 proteins, suggesting that chemotherapeutics targeting EGFR may be useful in preventing the progression of cancers that have altered Bcl-2 protein functions.

Indexed as

Neoplasm InvasivenessAntineoplastic AgentsApoptosisApoptosis Regulatory Proteinsbcl-X ProteinCell Line, TumorCell MovementDisease ProgressionErbB ReceptorsGefitinibHumansPhosphatidylinositol 3-KinasesPhosphorylationProto-Oncogene Proteins c-bcl-2QuinazolinesReactive Oxygen SpeciesAntineoplastic AgentsApoptosis Regulatory ProteinsBCL2L1 protein, humanBCL2L2 protein, humanbcl-X ProteinEGFR protein, humanErbB ReceptorsGefitinibPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-bcl-2QuinazolinesReactive Oxygen Speciessrc-Family KinasesBcl-2 familyCancerCell invasionEGFRSrc

Identifiers

PMID26286833
OpenAlexW1536022804

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.